{"generic":"Dasatinib","drugs":["Dasatinib","Sprycel"],"mono":{"0":{"id":"jwhfs0","title":"Generic Names","mono":"Dasatinib"},"1":{"id":"jwhfs1","title":"Dosing and Indications","sub":[{"id":"jwhfs1b4","title":"Adult Dosing","mono":"<ul><li><b>Philadelphia chromosome-positive acute lymphoblastic leukemia, Resistant or intolerant to prior therapy:<\/b> 140 mg ORALLY once a day with or without food; dose escalation to 180 mg\/day was allowed in patients who did not achieve a hematologic or cytogenetic response in clinical studies; continue until disease progression or intolerance<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Accelerated phase, resistant or intolerant to prior therapy:<\/b> 140 mg ORALLY once a day with or without food; dose escalation to 180 mg\/day was allowed in patients who did not achieve a hematologic or cytogenetic response in clinical studies; continue until disease progression or intolerance<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Blastic phase, resistant or intolerant to prior therapy:<\/b> 140 mg ORALLY once a day with or without food; dose escalation to 180 mg\/day was allowed in patients who did not achieve a hematologic or cytogenetic response in clinical studies; continue until disease progression or intolerance<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, newly diagnosed:<\/b> 100 mg ORALLY once daily, with or without food; dose escalation to 140 mg\/day was allowed in patients who did not achieve a hematologic or cytogenetic response in clinical studies; continue until disease progression or intolerance<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, resistant or intolerant to prior therapy:<\/b> 100 mg ORALLY once daily, with or without food; dose escalation to 140 mg\/day was allowed in patients who did not achieve a hematologic or cytogenetic response in clinical studies; continue until disease progression or intolerance<\/li><\/ul>"},{"id":"jwhfs1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients less than 18 years of age "},{"id":"jwhfs1b6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment:<\/b> no dosage adjustment necessary; use caution<\/li><li><b>myelosuppression in patients with chronic phase chronic myeloid leukemia (CML) who were started on 100 mg once daily:<\/b> for an absolute neutrophil count (ANC) less than 0.5 x 10(9)\/L OR platelets less than 50 x 10(9)\/L, interrupt dasatinib; when the ANC is at least 1 x 10(9)\/L AND platelets are at least 50 x 10(9)\/L, resume dasatinib at the original starting dose if recovery occurs within 7 days; if platelets are less than 25 x 10(9)\/L OR a recurrence of the ANC less than 0.5 x 10(9)\/L occurs for longer than 7 days, interrupt dasatinib; when the ANC is at least 1 x 10(9)\/L AND platelets are at least 50 x 10(9)\/L, resume dasatinib at a reduced dose of 80 mg ORALLY once daily if it is the second occurrence; if it is the third occurrence, reduce dose to 50 mg ORALLY once daily (for newly diagnosed patients) or discontinue therapy (for patients resistant or intolerant to prior therapy including imatinib)<\/li><li><b>myelosuppression in patients with accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who were started on 140 mg once daily:<\/b> for an absolute neutrophil count (ANC) less than 0.5 x 10(9)\/L OR platelets less than 10 x 10(9)\/L, interrupt dasatinib if the cytopenia is not related to the underlying leukemia (if cytopenia is related to the leukemia, consider dose escalation to 180 mg ORALLY once daily); when the ANC is at least 1 x 10(9)\/L AND platelets are at least 20 x 10(9)\/L, resume dasatinib at the original starting dose; if the cytopenia recurs, interrupt dasatinib if the cytopenia is not related to the underlying leukemia; when the ANC is at least 1 x 10(9)\/L AND platelets are at least 20 x 10(9)\/L, resume dasatinib at a reduced dose of 100 mg ORALLY once daily for second occurrence or 80 mg ORALLY once daily for third occurrence<\/li><li><b>nonhematological adverse events, severe:<\/b> interrupt dasatinib until the event has improved or resolved; resume dasatinib at a reduced dose depending on the severity of the adverse event<\/li><li><b>concomitant strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, St John's wort):<\/b> avoid St John's wort and avoid all others if possible; if concomitant administration cannot be avoided, consider increasing the dose of dasatinib with careful monitoring for toxicity<\/li><li><b>concomitant strong CYP3A4 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice):<\/b> avoid if possible; if concomitant administration cannot be avoided, consider decreasing the dasatinib dose to 20 mg in patients receiving 100 mg daily or to 40 mg orally daily in patients receiving 140 mg daily<\/li><\/ul>"},{"id":"jwhfs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Philadelphia chromosome-positive acute lymphoblastic leukemia, Resistant or intolerant to prior therapy<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Accelerated phase, resistant or intolerant to prior therapy<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Blastic phase, resistant or intolerant to prior therapy<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, newly diagnosed<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, resistant or intolerant to prior therapy<\/li><\/ul>"}]},"3":{"id":"jwhfs3","title":"Contraindications\/Warnings","sub":[{"id":"jwhfs3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jwhfs3b10","title":"Precautions","mono":"<ul><li>cardiac adverse events (ie, myocardial infarction, left ventricular dysfunction, congestive heart failure, cardiomyopathy, diastolic dysfunction, and left ventricular dysfunction), including fatal myocardial infarction, have been reported<\/li><li>concomitant use with H2-receptor antagonists or proton pump inhibitors is not recommended<\/li><li>concomitant use of strong CYP3A4 inducers is not recommended; if used, monitoring recommended; dose adjustment may be necessary<\/li><li>concomitant use with antacids, CYP3A4 inhibitors should be avoided<\/li><li>elderly patients; increased risk of toxicity<\/li><li>fluid retention, some cases severe (eg, pleural and pericardial effusion, severe pulmonary edema, severe ascites), has been reported<\/li><li>hemorrhages, including CNS (some cases fatal) and gastrointestinal (some cases fatal), have occurred; most bleeding events have been associated with severe thrombocytopenia<\/li><li>myelosuppression, severe (grade 3 or 4 thrombocytopenia, neutropenia, and anemia), has been reported; monitoring and dose adjustment recommended<\/li><li>pulmonary arterial hypertension (PAH) may occur, including after more than 1 year of treatment; monitoring recommended; discontinue if PAH is confirmed<\/li><li>QTc prolongation has been reported; use caution in patients with QTc prolongation or at increased risk (eg, congenital long QT syndrome, concurrent use of antiarrhythmic medications, other medications which cause QT prolongation, cumulative high-dose anthracycline therapy, hypokalemia or hypomagnesemia); correct hypokalemia and hypomagnesemia prior to dasatinib administration<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jwhfs3b11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"jwhfs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jwhfs4","title":"Drug Interactions","sub":[{"id":"jwhfs4b13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"jwhfs4b14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cimetidine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Esomeprazole (theoretical)<\/li><li>Famotidine (established)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nizatidine (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Ranitidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (probable)<\/li><li>Ritonavir (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"},{"id":"jwhfs4b15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (established)<\/li><li>Aluminum Hydroxide (established)<\/li><li>Aluminum Phosphate (established)<\/li><li>Calcium (established)<\/li><li>Calcium Carbonate (established)<\/li><li>Dihydroxyaluminum Aminoacetate (established)<\/li><li>Dihydroxyaluminum Sodium Carbonate (established)<\/li><li>Magaldrate (established)<\/li><li>Magnesium Carbonate (established)<\/li><li>Magnesium Hydroxide (established)<\/li><li>Magnesium Oxide (established)<\/li><li>Magnesium Trisilicate (established)<\/li><li>Simvastatin (established)<\/li><li>Sodium Bicarbonate (established)<\/li><\/ul>"}]},"5":{"id":"jwhfs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Body fluid retention (All grades, 21% to 42%; grade 3 or 4, 3% to 8%), Localized edema, Superficial (All grades, 3% to 21%; grade 3 or 4, 1%)<\/li><li><b>Dermatologic:<\/b>Rash (all grades, 10% to 20% or greater; grade 3 or 4, 2%)<\/li><li><b>Endocrine metabolic:<\/b>Hypocalcemia, Grade 3 or 4 (up to 12%), Hypokalemia, Grade 3 or 4 (2% to 15%), Hypophosphatemia, Grade 3 or 4 (5% to 18%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (all grades, 3% to 12%; grade 3 or 4, up to 3%), Diarrhea (all grades, 3% to 31%; grade 3 or 4, up to 5%), Nausea (all grades, 9% to 24%; grade 3 or 4, up to 3%), Vomiting (all grades, 5% to 16%; grade 3 or 4, up to 1%)<\/li><li><b>Hematologic:<\/b>Myelosuppression (10% or greater)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (all grades, 8% to 19%; grade 3 or 4, up to 2%)<\/li><li><b>Neurologic:<\/b>Headache (all grades, 10% to 33%; grade 3 or 4, up to 3%)<\/li><li><b>Respiratory:<\/b>Dyspnea (All grades, 3% to 24%; grade 3 or 4, 2% to 3%)<\/li><li><b>Other:<\/b>Fatigue (all grades, 8% to 24%; grade 3 or 4, less than 1% to 3%), Fever (all grades, 1% to 18%; grade 3 or 4, 1% to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure, Or cardiac dysfunction (All grades, up to 4%; grade 3 or 4, less than 1%), Pericardial effusion (All grades, 1% to 3%; grade 3 or 4, 1% or less), Prolonged QT interval (1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (all grades, 2% to 9%; grade 3 or 4, 1% to 7%), Hemorrhagic colitis<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (11% to 74%), Bleeding (all grades, 2% to 26%), Bleeding, Grade 3 or 4 (1% to 9%), Febrile neutropenia (1% to 12%), Neutropenia, Grade 3 or 4 (22% to 79%), Thrombocytopenia, Grade 3 or 4 (19% to 85%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, Grade 3 or 4 (up to 5%), Ascites (less than 1%), AST\/SGOT level raised, Grade 3 or 4 (up to 4%), Hepatitis, Serum bilirubin raised, Grade 3 or 4 (up to 6%)<\/li><li><b>Immunologic:<\/b>Infectious disease (All grades, 2% to 14%; grades 3 or 4, up to 7%)<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage (1% to 3%; grade 3 or 4, 1% to 3%)<\/li><li><b>Renal:<\/b>Serum creatinine raised, Grade 3 or 4 (up to 8%)<\/li><li><b>Respiratory:<\/b>Pleural effusion (All grades, 19% to 24%; grade 3 or 4, 2% to 11%), Pneumonia (1% to less than 10%), Pulmonary edema (All grades, up to 4%; grade 3 or 4, up to 3%), Pulmonary hypertension (All grades, 1% to less than 10%; grade 3 or 4, less than 1%)<\/li><li><b>Other:<\/b>Sepsis (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"jwhfs6","title":"Drug Name Info","sub":{"0":{"id":"jwhfs6b17","title":"US Trade Names","mono":"Sprycel<br\/>"},"2":{"id":"jwhfs6b19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Tyrosine Kinase Inhibitor<\/li><\/ul>"},"3":{"id":"jwhfs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jwhfs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jwhfs7","title":"Mechanism Of Action","mono":"Dasatinib is an inhibitor of multiple tyrosine kinases that is indicated for the treatment of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. It suppresses the growth and proliferation of leukemic cell lines over-expressing BCR-ABL and inhibits alternate signaling pathways involving the SRC family kinases.<br\/>"},"8":{"id":"jwhfs8","title":"Pharmacokinetics","sub":[{"id":"jwhfs8b23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 0.5 to 6 hours<\/li><li>Effect of food: minimal<\/li><\/ul>"},{"id":"jwhfs8b24","title":"Distribution","mono":"<ul><li>Vd: adults, 2505 L<\/li><li>Protein binding: approximately 96%<\/li><\/ul>"},{"id":"jwhfs8b25","title":"Metabolism","mono":"Hepatic: extensive via P450 CYP3A4 <br\/>"},{"id":"jwhfs8b26","title":"Excretion","mono":"<ul><li>Fecal: adults, 85%, 19% unchanged<\/li><li>Renal: adults, 4%, 0.1% unchanged<\/li><\/ul>"},{"id":"jwhfs8b27","title":"Elimination Half Life","mono":"Adults: 3 to 5 hours <br\/>"}]},"9":{"id":"jwhfs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>follow procedures for proper handing and disposal of anticancer drugs<br\/><\/li><li><b>Oral<\/b><br\/><ul><li>tablets should be swallowed whole; do not crush or cut tablets, because of protective film coating around active drug; if tablets are crushed or broken, use protective chemotherapy gloves<\/li><li>pregnant women should avoid exposure to crushed or broken tablets<\/li><li>take with or without a meal<\/li><li>take antacids at least 2 hours prior to or 2 hours after the dose of dasatinib<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jwhfs10","title":"Monitoring","mono":"<ul><li>bone marrow aspiration and bone marrow biopsy to measure cytogenetic response every 1 to 3 months as an indication of therapy effectiveness<\/li><li>CBC; weekly for the first 2 months of therapy and then monthly thereafter or as clinically indicated, including differential<\/li><li>signs and symptoms of bleeding, infection, pleural effusion (shortness of breath, chest pain, cough), and edema (weight gain)<\/li><li>signs and symptoms of pulmonary arterial hypertension, prior to and during therapy<\/li><\/ul>"},"11":{"id":"jwhfs11","title":"How Supplied","mono":"<b>Sprycel<\/b><br\/>Oral Tablet: 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, 140 MG<br\/>"},"12":{"id":"jwhfs12","title":"Toxicology","sub":[{"id":"jwhfs12b31","title":"Clinical Effects","mono":"<b>DASATINIB<\/b><br\/>OVERDOSE: Human data are limited. Expected effects include myelosuppression, bleeding complications, fluid retention, QT prolongation with possible ventricular dysrhythmias, hypocalcemia, hypophosphatemia and elevations in serum aminotransferases. THERAPEUTIC ADVERSE EFFECTS: Myelosuppression is common, and is usually the dose-limiting toxic effect. COMMON: Fluid retention (50%) (including peripheral edema, CHF, ascites, pleural effusion, and pericardial effusion), diarrhea (49%), nausea (34%), vomiting (22%), abdominal pain (25%), and bleeding events (40%) are frequent events. SERIOUS: Fever (9%), pleural effusion (8%), febrile neutropenia (7%), gastrointestinal bleeding (6%), pneumonia (6%), thrombocytopenia (5%), dyspnea (5%), anemia (3%), cardiac failure (3%), and diarrhea (2%).<br\/>"},{"id":"jwhfs12b32","title":"Treatment","mono":"<b>DASATINIB<\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Myelosuppression: Filgrastim 5 mcg\/kg\/day subcutaneously or sargramostim 250 mcg\/m(2)\/day intravenously over 4 hours may be useful for severe or febrile neutropenia. Packed red cell and\/or platelet transfusion may be needed in patients with severe thrombocytopenia, anemia, or hemorrhage.<\/li><li>Torsades de pointes: Not reported, but may develop secondary to QTc prolongation. Correct hypocalcemia and hypophosphatemia. Administer intravenous MAGNESIUM SULFATE. ADULT: 2 g IV over 1 to 2 min, repeat 2 g bolus and begin infusion of 0.5 to 1 g\/hr if dysrhythmias recur. CHILD: 25 to 50 mg\/kg diluted to 10 mg\/mL; infuse IV over 5 to 15 min. Overdrive pacing may be needed.<\/li><li>Monitoring of patient: Monitor serial CBC with differential and platelet counts. Monitor serum electrolytes including calcium and phosphorus, serum aminotransferase and bilirubin concentrations. Monitor ECG for evidence of QT prolongation.<\/li><li>Enhanced elimination procedure: Unlikely to be useful because of dasatinib's large volume of distribution.<\/li><\/ul>"},{"id":"jwhfs12b33","title":"Range of Toxicity","mono":"<b>DASATINIB<\/b><br\/>TOXICITY: Limited data. A single ingestion of 200 mg in one patient did not result in symptoms or laboratory evidence of toxicity. THERAPEUTIC DOSE: ADULT: 70 mg administered orally twice daily. <br\/>"}]},"13":{"id":"jwhfs13","title":"Clinical Teaching","mono":"<ul><li>Advise patient on proper handling and disposal of chemotherapy drugs. Pregnant women should avoid exposure to crushed or broken tablets.<\/li><li>Drug may cause diarrhea, nausea, vomiting, headache, fatigue, dyspnea, rash, musculoskeletal pain, myelosuppression, and hemorrhage.<\/li><li>Instruct patient to report signs\/symptoms of myelosuppression (fever, infection) or hemorrhage.<\/li><li>Patient should immediately report signs\/symptoms of pulmonary arterial hypertension (eg, fluid retention, fatigue, shortness of breath).<\/li><li>Advise patient to report significant adverse events.<\/li><li>Patient should not eat grapefruit or drink grapefruit juice while taking this drug.<\/li><li>Instruct patient to wait at least 2 hours before or after drug to take an antacid.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult doctor prior to new drug use, including over-the-counter and herbal drugs.<\/li><\/ul>"}}}